Update in Addiction Medicine: Spotlight on Alpha-2 Agonists

Alpha-2 agonists, including medetomidine and xylazine, are currently adulterating the unregulated fentanyl supply in Southwestern Pennsylvania. While both are veterinary sedatives, they have different medical consequences. In this talk, Drs. Roy and Shang will review the epidemiology of alpha-2 agonist adulteration, describe the recognition and management of alpha-2 agonist toxicity and withdrawal and the role of the Substance Treatment and Recovery Service, review practical strategies to reduce harms from alpha-2 agonists, and review the management of xylazine-associated wounds and the dedicated WoundWell clinic.

Target Audience

This course is designed for health care professionals including physicians, nurses, patients and caregivers, among others.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the epidemiology and clinical effects of novel adulterants in the unregulated opioid supply.
  • Recognize and manage withdrawal associated with alpha-2 adrenergic adulterants.
  • Apply strategies to reduce risks associated with an evolving unregulated drug supply.
  • Identify opportunities for health systems to adapt clinical services in response to changes in the unregulated drug supply.

Course summary

Available credit: 
  • 1.00 ABIM MOC II
  • 1.00 AMA PRA Category 1 Credit™
    The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
    • 1.00 Opioid Education
  • 1.00 Attendance
Course opens: 
09/22/2026
Course expires: 
09/22/2029

Payel Jhoom Roy, MD, MSc — Associate Professor of Medicine
Clinical Director, Substance Treatment and Recovery Services (STARS)
Department of Meidicine, University of Pittsburgh
No relationships with industry relevant to the content of this educational activity have been disclosed.

Margaret Shang, MD, MS — Assistant Professor of Medicine and Pediatrics
Program Director, Adolescent and Young Adult Addiction Medicine Fellowship
Department of Medicine, University of Pittsburgh
No relationships with industry relevant to the content of this educational activity have been disclosed.


Disclosures:
No members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Disclaimer Statement:
The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

 

Accreditation Statement

Jointly Accredited Provider Mark

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Pittsburgh designates enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit[s]™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn ABIM MOC points equivalent to the amount of CME credits claimed for the activity.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

DEA Medication Access and Training Expansion (MATE) Act
This training is designed to meet the training requirements for the Medication Access and Training Expansion (MATE) Act of 2023.

Pennsylvania Opioid/Pain Management Credit (physicians only)
This activity has been designated as and qualifies for Opioid/Pain Management Credit. It is the responsibility of the learner to maintain the educational presentation or conference agenda as evidence, if needed for audit purpose

Available Credit

  • 1.00 ABIM MOC II
  • 1.00 AMA PRA Category 1 Credit™
    The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
    • 1.00 Opioid Education
  • 1.00 Attendance
Please login or register to take this course.